GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (XTER:FYB) » Definitions » Sale Of Business

Formycon AG (XTER:FYB) Sale Of Business : €0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Formycon AG Sale Of Business?

Formycon AG's sale of business for the six months ended in Dec. 2024 was €0.00 Mil. It means Formycon AG gained €0.00 Mil from selling business. Formycon AG's sale of business for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Jun. 2024 ), Formycon AG gained the same money from selling business in Dec. 2024 (€0.00 Mil).


Formycon AG Sale Of Business Historical Data

The historical data trend for Formycon AG's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formycon AG Sale Of Business Chart

Formycon AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Sale Of Business
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.11 - -

Formycon AG Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Sale Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Formycon AG Sale Of Business Calculation

The amount earned to sell business.


Sale Of Business for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Formycon AG Sale Of Business Related Terms

Thank you for viewing the detailed overview of Formycon AG's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


Formycon AG Business Description

Traded in Other Exchanges
Address
Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is a globally operating, independent biosimilars specialist with a comprehensive product pipeline and a scalable platform for developing biosimilar drugs for various indications, including ophthalmology, immunology, and immunobiology. Its product, FYB201 (ranibizumab), is an approved biosimilar product for Lucentis, is on the market in the United States and Canada, Europe, the Middle East and North Africa (MENA), and other geographical regions. The other product candidates in its pipeline include FYB202, FYB203, FYB206, FYB207, FYB208, FYB209, and FYB210, which are biosimilar projects being developed for the treatment of various indications. Geographically, the company generates maximum revenue from Switzerland, followed by Germany.
Executives
Dr. Nicola Mikulcik Board of Directors
Dr. Stefan Glombitza Board of Directors
Dr. Carsten Brockmeyer Board of Directors
Dr. Nicolas Combé Board of Directors

Formycon AG Headlines

No Headlines